跳至主要内容
临床试验/NCT03391778
NCT03391778Enrolling By Invitation1 期

Long-Term Follow-Up (LTFU) of Participants Treated With ADP Adoptive Cell Therapies

USWM CT, LLC36 个研究点 分布在 8 个国家目标入组 250 人开始时间: 2018年4月9日最近更新:
适应症
干预措施

试验速览

阶段
1 期
状态
Enrolling By Invitation
发起方
USWM CT, LLC
入组人数
250
试验地点
36
主要终点
Number of participants with delayed adverse events (AEs) and serious adverse events (SAEs)

研究概览

简要总结

This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.

详细描述

Participants who received a ADP adoptive cell therapy will be enrolled in this non-therapeutic, multi-center, long term follow-up (LTFU) study and will be followed for up to 15 years post-infusion of lentiviral vector-based adoptive cell therapy. Participants will be monitored for safety following last adoptive cell therapy infusion.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

性别
All
接受健康志愿者

入选标准

  • Participants who have received at least one dose of ADP adoptive cell therapy agent.
  • Participants who have completed ADP sponsored or supported interventional study or have withdrawn from it.
  • Participants who have completed treatment as part of managed access to a GSK adoptive cell therapy.
  • Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • The investigator is responsible for review of medical history.
  • Capable of giving signed informed consent.

排除标准

  • 未提供

研究组 & 干预措施

Participants receiving ADP adoptive cell therapy

Experimental

干预措施: ADP adoptive cell therapy (Biological)

结局指标

主要结局

Number of participants with delayed adverse events (AEs) and serious adverse events (SAEs)

时间窗: 15 years post last treatment

AEs will be collected.

次要结局

  • Number of participants with Woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) or Psi DNA copies in peripheral blood samples.(15 years)
  • Time to death(15 years)
  • Number of participants with Vesicular Stomatitis Virus G protein (VSV-G) Deoxyribonucleic acid (DNA) copies in peripheral blood samples(15 years)
  • Number of deaths(15 years)
  • Number of participants with integrated vector sequences and vector integration patterns identified in peripheral blood samples(15 years)

研究者

发起方
USWM CT, LLC
申办方类型
Industry
责任方
Sponsor

研究点 (36)

Loading locations...

相似试验